Title of article :
Variability of Individual Platelet Reactivity Over Time in Patients Treated With Clopidogrel: Insights From the ELEVATE–TIMI 56 Trial
Author/Authors :
Hochholzer، نويسنده , , Willibald and Ruff، نويسنده , , Christian T. and Mesa، نويسنده , , Robert A. and Mattimore، نويسنده , , John F. and Cyr، نويسنده , , John F. and Lei، نويسنده , , Lanyu and Frelinger III، نويسنده , , Andrew L. and Michelson، نويسنده , , Alan D. and Berg، نويسنده , , David D. and Angiolillo، نويسنده , , Dominick J. and OʹDonoghue، نويسنده , , Michelle L. and Sabatine، نويسنده , , Marc S. and Mega، نويسنده , , Jessica L.، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2014
Pages :
8
From page :
361
To page :
368
Abstract :
AbstractBackground gree of antiplatelet response to clopidogrel has been associated with clinical outcomes. Studies have investigated whether adjustment of antiplatelet therapies based on a single platelet function test is beneficial. ives m of the study was to test the stability of platelet reactivity measurements over time among patients treated with standard and double doses of clopidogrel. s EVATE–TIMI 56 (Escalating Clopidogrel by Involving a Genetic Strategy–Thrombolysis In Myocardial Infarction 56) investigators genotyped 333 patients with coronary artery disease and randomized them to various clopidogrel regimens. Patients with at least 2 platelet function results on the same maintenance dose of clopidogrel (75 mg or 150 mg) were analyzed. Platelet aggregation was measured using P2Y12 reaction units (PRU). s al, the mean platelet reactivity and the total number of nonresponders (PRU ≥230) with clopidogrel did not change between 2 periods for the 75-mg (22.4% vs. 21.9%; p = 0.86) and 150-mg doses of clopidogrel (11.5% vs. 11.5%; p = 1.00). In contrast, when evaluating each patient individually, 15.7% of patients taking clopidogrel 75 mg and 11.4% of patients taking 150 mg had a change in their responder status when tested at 2 different time points (p < 0.001). Despite being treated with the same dose of clopidogrel, >40% of patients had a change in PRU >40 on serial sampling, which approximates the average PRU difference caused by increasing the clopidogrel dose from 75 mg to 150 mg. sions ements of platelet reactivity vary over time in a significant proportion of patients. Thus, treatment adjustment according to platelet function testing at a single time point might not be sufficient for guiding antiplatelet therapy in clinical or research settings. (Escalating Clopidogrel by Involving a Genetic Strategy–Thrombolysis In Myocardial Infarction 56 [ELEVATE–TIMI 56]; NCT01235351)
Keywords :
nonresponder , Clopidogrel , Platelet reactivity , Variability
Journal title :
JACC (Journal of the American College of Cardiology)
Serial Year :
2014
Journal title :
JACC (Journal of the American College of Cardiology)
Record number :
1758972
Link To Document :
بازگشت